-+ 0.00%
-+ 0.00%
-+ 0.00%

Royalty Pharma publishes transcript of Q2 2026 financial results call

PUBT·08/11/2026 13:58:47
Listen to the news
Royalty Pharma publishes transcript of Q2 2026 financial results call
  • Royalty Pharma’s Q2 2026 results call drew CEO Pablo Legorreta, EVP Marshall Urist, Chairman of Partnering & Investments Christopher Hite, CFO Terrance Coyne, and analysts from Citi, Morgan Stanley, JPMorgan, TD Cowen, UBS, Evercore, Goldman Sachs, and BofA.
  • Raised 2026 guidance to Portfolio Receipts of USD 3.4-3.5 billion; Royalty Receipts growth seen at 7%-10% despite Promacta LOE and US biosimilar Tysabri.
  • Q2 Portfolio Receipts rose 6% to USD 773 million; Royalty Receipts increased 14%; Portfolio Cash Flow reached USD 736 million on a roughly 95% margin.
  • Agreed to buy a 3.75% worldwide net-sales royalty on AstraZeneca’s cliramitug for up to USD 425 million; Phase 3 ATTR-CM outcomes data expected in 2028.
  • CFO flagged interest-paid seasonality, reiterating milestones and other contractual receipts of about USD 60 million for 2026; leverage ended Q2 at 2.8x debt/Adjusted EBITDA.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Royalty Pharma plc published the original content used to generate this news brief on August 11, 2026, and is solely responsible for the information contained therein.